These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 2579648)

  • 61. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.
    Zhang H; Zhang S; Cheung NK; Ragupathi G; Livingston PO
    Cancer Res; 1998 Jul; 58(13):2844-9. PubMed ID: 9661900
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Structural characterization and in vivo immunosuppressive activity of neuroblastoma GD2.
    Li R; Gage D; McKallip R; Ladisch S
    Glycoconj J; 1996 Jun; 13(3):385-9. PubMed ID: 8781969
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Isolation and characterization of gangliosides from Theileria sergenti.
    Watarai S; Sugimoto C; Hosotani-Kaihara K; Kobayashi K; Onuma M; Lee JT; Kushi Y; Handa S; Yasuda T
    J Vet Med Sci; 1996 Nov; 58(11):1099-105. PubMed ID: 8959658
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The 3G11+ antigen, a marker for murine CD4+ TH1 lymphocytes, is a ganglioside.
    Greer JM; Koerner TA; Hayakawa K; Hardy RR; Kemp JD
    Glycobiology; 1993 Aug; 3(4):391-401. PubMed ID: 7691279
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Disialoganglioside directed immunotherapy of neuroblastoma.
    Modak S; Cheung NK
    Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.
    Horwacik I; Durbas M; Boratyn E; Węgrzyn P; Rokita H
    Cancer Lett; 2013 Dec; 341(2):248-64. PubMed ID: 23962557
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
    Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.
    Miederer M; McDevitt MR; Borchardt P; Bergman I; Kramer K; Cheung NK; Scheinberg DA
    Clin Cancer Res; 2004 Oct; 10(20):6985-92. PubMed ID: 15501978
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.
    Cheung NK; Saarinen UM; Neely JE; Landmeier B; Donovan D; Coccia PF
    Cancer Res; 1985 Jun; 45(6):2642-9. PubMed ID: 2580625
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8.
    Bergman I; Arbit E; Rosenblum M; Larson SM; Heller G; Cheung NK
    J Neurooncol; 1993 Mar; 15(3):235-42. PubMed ID: 8360709
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Anti-GD2 immunotherapy for neuroblastoma.
    Sait S; Modak S
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
    [TBL] [Abstract][Full Text] [Related]  

  • 73. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.
    Cheung NK; Kushner BH; Yeh SD; Larson SM
    Int J Oncol; 1998 Jun; 12(6):1299-306. PubMed ID: 9592190
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.
    Mujoo K; Cheresh DA; Yang HM; Reisfeld RA
    Cancer Res; 1987 Feb; 47(4):1098-104. PubMed ID: 3100030
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.
    Alvarez-Rueda N; Desselle A; Cochonneau D; Chaumette T; Clemenceau B; Leprieur S; Bougras G; Supiot S; Mussini JM; Barbet J; Saba J; Paris F; Aubry J; Birklé S
    PLoS One; 2011; 6(9):e25220. PubMed ID: 21966461
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Availability of conjugated ganglioside GD2 monoclonal antibody.
    Warzynski MJ; Roys JL; Peterson JW; DeLa Vega H
    Cytometry B Clin Cytom; 2005 May; 65(1):42-3. PubMed ID: 15806571
    [No Abstract]   [Full Text] [Related]  

  • 77. Monoclonal antibody directed to a Hanganutziu-Deicher active ganglioside, GM2 (NeuGc).
    Sanai Y; Yamasaki M; Nagai Y
    Biochim Biophys Acta; 1988 Feb; 958(3):368-74. PubMed ID: 2449247
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography.
    Hamilton WB; Helling F; Lloyd KO; Livingston PO
    Int J Cancer; 1993 Feb; 53(4):566-73. PubMed ID: 8436430
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library.
    Horwacik I; Czaplicki D; Talarek K; Kowalczyk A; Bolesta E; Kozbor D; Rokita H
    Int J Mol Med; 2007 May; 19(5):829-39. PubMed ID: 17390090
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis.
    Cheresh DA; Rosenberg J; Mujoo K; Hirschowitz L; Reisfeld RA
    Cancer Res; 1986 Oct; 46(10):5112-8. PubMed ID: 3019521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.